Matt Tiffany

Title: Matt Tiffany: Innovator in AAV Vector Technology

Introduction

Matt Tiffany is a prominent inventor based in San Mateo, CA (US). He has made significant contributions to the field of gene therapy through his innovative work on adeno-associated virus (AAV) vectors. His research focuses on enhancing the capabilities of these vectors, which are crucial for delivering genetic material into cells.

Latest Patents

Matt Tiffany holds a patent for "AAV vectors with expanded packaging capacity." This invention relates to AAV vectors that encode variant capsid polypeptides, which are more cationic compared to non-variant parent capsid polypeptides. The significance of this patent lies in its ability to allow the vector comprising the variant capsid polypeptide to accommodate longer nucleic acid inserts, thereby improving the efficiency of gene delivery.

Career Highlights

Matt Tiffany is affiliated with Leland Stanford Junior University, where he conducts his research and development in the field of gene therapy. His work has garnered attention for its potential applications in treating various genetic disorders. With 1 patent to his name, he continues to push the boundaries of what is possible in genetic engineering.

Collaborations

One of his notable collaborators is Mark A. Kay, a respected figure in the field of gene therapy. Their partnership exemplifies the collaborative spirit of scientific research, as they work together to advance the understanding and application of AAV vectors.

Conclusion

Matt Tiffany's contributions to AAV vector technology represent a significant advancement in the field of gene therapy. His innovative approach and dedication to research continue to inspire future developments in genetic engineering.